Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Ohio - United States Bill to ban sale of intoxicating hemp products unlikely to move forward ...
  • Europe European Council adopts regulation to reduce and recycle packaging ...
  • Germany Two Berlin districts to start recreational cannabis sales ...
  • Nebraska - United States Two cannabis measures signed into law ...
  • Brazil AGU requests extension on deadline for cannabis regulations ...
  • Switzerland Bern recreational cannabis project extended ...
  • Japan Law in force today criminalises recreational and legalises medical cannabis ...
  • Germany ‘Not the second pillar’ as BMEL issues rules on cannabis research projects ...
  • France Restart of experiment on medical cannabis could be pushed to 2026 ...
  • Florida - United States Letters of intent to approve medical marijuana permits issued ...
  • Netherlands Experimental phase of controlled cannabis experiment starts 7th April ...
  • Germany Government comments on Industrial Hemp Liberalisation bill ...
View all
News analysis

German pharma firm buys €80m C3 to boost its European cannabis presence

Written by || 26th January 2022 || News analysis | Companies | GeographiesCanada Europe Germany North America

This story examines the significance of German pharma group Dermapharm’s acquisition of the Germany based Cannabinoid Compound Company (C3) from Canadian owner Canopy Growth. We show how it’s an opportunity for Dermapharm to expand in the European medical cannabis market, but represents a considerable loss for Canopy after only three years’ ownership.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.